Hepatocellular-Cholangiocarcinomas in Non-Alcoholic Fatty Liver Disease: Evidence for Stem Cell Origin

  • Paulo Giovanni Mendoza National Kidney & Transplant Institute
  • Wilson Tsui Department of Pathology, Caritas Medical Centre, Hong Kong
  • Lorraine Ho Department of Radiology, Caritas Medical Centre, Hong Kong
  • Michael Wayne Department of Surgery, Beth Israel Medical Center of Albert Einstein College of Medicine, New York, New York
  • Alexander Kagen Department of Radiology, Icahn School of Medicine at Mount Sinai, Mount Sinai West, Mount Sinai St. Luke’s, New York
  • Neil Theise Departments of Pathology and Medicine (Division of Digestive Diseases), Beth Israel Medical Center of Albert Einstein College of Medicine, New York, New York http://orcid.org/0000-0002-4048-5140
Keywords: hepatocellular-cholangiocarcinoma, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, stem cell


The authors present two cases of combined hepatocellular-cholangiocarcinoma in a background of non-cirrhotic, non-alcoholic fatty liver disease (NAFLD). The increasing incidence of NAFLD and the subsequent recognition of it being a pre-malignant condition even in the absence of significant fibrosis or established cirrhosis has led to the investigations of the different pathways involved in NAFLD-associated hepatocarcinogenesis, including speculations regarding the possibility that many derive from pre-malignant hepatocellular adenomas, tumors also increasingly associated with NAFLD, or reflect malignant transformation of mature hepatocytes through genetic and epigenetic alterations reflecting inflammatory changes in NAFLD. However, NAFLD, like most chronic liver diseases, leads to progressive activation of resident hepatobiliary stem/progenitor cells that are thought to give rise to malignant tumors in other settings. In particular, combined hepatocellular-cholangiocarcinomas (with and without stem cell features) are thought to reflect malignant transformation of these activated progenitors. Our two cases of combined hepatocellular-cholangiocarcinomas suggest that malignant transformation of hepatobiliary stem/progenitor cells in NAFLD are also a possible pathway to malignancy, even in the absence of established cirrhosis.

Author Biography

Paulo Giovanni Mendoza, National Kidney & Transplant Institute

Department of Pathology and Laboratory Medicine


Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver

disease and hepatocellular carcinoma: a weighty connection.

Hepatology. 2010;51(5);1820-32. https://doi.org/10.1002/


Paradis V, Zalinski S, Chelbi E. et al. Hepatocellular

carcinomas in patients with metabolic syndrome often develop

without significant liver fibrosis: a pathological analysis.

Hepatology. 2009;49(3); 851-9. https://doi.org/10.1002/


Guzman G, Brunt EM, Petrovic M, Chejfec G, Layden TJ,

Cotler SJ. Does nonalcoholic fatty liver disease predispose

patients to hepatocellular carcinoma in the absence of cirrhosis?

Arch Pathol Lab Mab. 2008;132(11);1761-6. https://doi.

org/10.1043/1543-2165-132.11.1761. PMID: 18976012.

Bullock RE, Zaitoun AM, Aithal GP, Ryder SD, Beckingham

IJ, Lobo DN. Association of non-alcoholic steatohepatitis

without significant fibrosis with hepatocellular carcinoma.

J Hepatol. 2004;41(4);685-6. https://doi.org/10.1016/j.


Saxena R. Practical hepatic pathology: a diagnostic approach.

Philadelphia: Elsevier-Saunders, 2011.

Herzer K, Hofmann TG, Teufel A, et al. IFN-alphainduced

apoptosis in hepatocellular carcinoma involves

promyelocytic leukemia protein and TRAIL independently

of p53. Cancer Res. 2009;69; 855-62. https://doi.


Cazanave SC, Mott JL, Elmi NA, et al. JNK1-dependent

PUMA expression contributes to hepatocyte lipoapoptosis. J

Biol Chem. 2009;284; 26591-602. https://doi.org/10.1074/


Ertle J, Dechêne A, Sowa J, et al. Non-alcoholic fatty liver

disease progresses to hepatocellular carcinoma in the absence

of apparent cirrhosis. Int J Cancer. 2011; 128(10):2436-43.


Theise ND, Nakashima O, Park YN, Nakanuma Y. Combined

hepatocellular-cholangicarcinoma. In: Bosman FT, Carneiro

F, Hruban RH, Theise ND, eds. WHO Classification of

tumours of the digestive system. Lyon: IARC;2010, pp. 225-7.

Theise ND, Yao JL, Harada K, et al. Hepatic “stem

cell” malignancies in adults: four cases. Histopathology.

;43(3);263-71. https://doi.org/10.1046/j.1365-2559.2003.

x. PMID: 12940779.

Yoon SM, Gerasimidou D, Kuwahara R, et al. Epithelial

cell adhesion molecule (EpCAM) marks hepatocytes newly

derived from stem/progenitor cells in humans. Hepatology.

;53(3);964-73. https://doi.org/10.1002/hep.24122.

Brunt EM. Nonalcoholic steatohepatitis. Semin Liver

Dis.2004;24(1);3-20. https://doi.org/10.1055/s-2004-823098.

Harrison SA, Torgerson S, Hayashi PH. The natural history

of nonalcoholic fatty liver disease: a clinical histopathological

study. Am J Gastroenterol. 2003;98;2042-7. https://doi.


Adams LA, Sanderson S, Limdor KD, Angulo P. The

histological course of nonalcoholic fatty liver disease: a

longitudinal study of 103 patients with sequential liver biopsies.

J Hepatol .2005;42(1);132-8. https://doi.org/10.1016/j.


Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C.

Natural history of nonalcoholic steatohepatitis: a longitudinal

study of repeat liver biopsies. Hepatology. 2004;40(4);820-6.


Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME,

Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for

treatment of nonalcoholic steatohepatitis: results of a

randomized trial. Hepatology. 2004;39(3);770-8. https://doi.


Caldwell Sh, Oelsner DH, Iezzoni JC, Hespenheide EE,

Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical

characterization and risk factors for underlying disease.

Hepatology. 1999;29(3);664-9. https://doi.org/10.1002/


Bugianesi E, Leone N, Vann E, et al. Expanding the natural

history of nonalcoholic steatiohepatitis: from cryptogenic

cirrhosis to hepatocellular carcinoma. Gastroenterology.

;123(1);134-140. https://doi.org/10.1053/gast.2002.

Hai S, Kubo S, Shuto T, et al. Hepatocellular carcinoma

arising from nonalcoholic steatohepatitis: report of two cases.

Surg Today. 2006;36(4);390-4. https://doi.org/10.1007/


Mori S, Yamasaki T, Sakaida I et al. Hepatocellular

carcinoma with nonalcoholic steatohepatitis. J Gastroenterol.

;39(4);391-6. https://doi.org/10.1007/s00535-003-


Cuadrado A, Orive A, Garcia-Suárez C, et al. Nonalcoholic

steatohepatitis (NASH) and hepatocellular

carcinoma. Obes Surg. 2005;15(3);442-6. https://doi.


Regimbeau JM, Colombat M, Mognol P, et al. Obesity and

diabetes as a risk factor for hepatocellular carcinoma. Liver

Transpl. 2004;10(Suppl 2);S69-73. https://doi.org/10.1002/


Stoot JHMB, Coelen RJS, De Jong MC, Dejong CHC.

Malignant transformation of hepatocellular adenomas into

hepatocellular carcinomas: a systematic review including

more than 1600 adenoma cases. HPB. 2010;12(8);509-22.


Paradis V, Laurent A, Flejou JF, Vidaud M, Bedossa P.

Evidence for the polyclonal nature of focal nodular hyperplasia

of the liver by the study of X-chromosome inactivation.

Hepatology. 1997;26(4);891-5. https://doi.org/10.1002/


Farges O, Dokmak S. Malignant transformation of

liver adenoma: an analysis of the literature. Dig Surg.

;27(1);32-8. https://doi.org/10.1159/000268405.

Unger RH, Orci L. Lipoapoptosis: its mechanism and its

diseases. BBA-Mol Cell Biol L. 2002;1585(2-3); 202-12.

Puri P, Mirshahi F, Cheung O, et al. Gastroenterology.

;134(2):568-76. https://doi.org/10.1053/j.gastro.2007.


Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja

MJ. Hepatology. 2009; 49(1);87-96. https://doi.org/10.1002/


Schattenberg JM, Singh R, Wang Y, et al. JNK1 but not

JNK2 promotes the development of steatohepatitis in mice.

Hepatology. 2006;43:163-72.

Clouston A, Powell E. Interaction of non-alcoholic fatty

liver disease with other liver diseases. Best Pract Res Clin

Gastroenterol. 2002;16(5);767-81. https://doi.org/10.1053/


Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin

Liver Dis. 2007;11(1):191-207,x-xi. PMID: 17544979.

Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, et

al. Mitochondrial adaptations to obesity-related oxidant stress.

Arch Biochem Biophys. 2000;378(2);259-68. https://doi.


Chen F, Beezhold k, Castranova V. JNK1, a potential

therapeutic target for hepatocellular carcinoma. BBA-Rev

Cancer. 2009;1796(2);242-51. http://dx.doi.org/10.1016/j.


Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity

promote liver inflammation and tumorigenesis by enhancing

IL-6 and TNF expression. Cell. 2010;140(2);197-208. https://


Hatziapostolou M, Polytarchou C, Aggelidou E, et al. An

HNF4a-miRNA inflammatory feedback circuit regulates

hepatocellular oncogenesis. Cell. 2011;147(6);1233-47.


Clouston AD, Powell EE, Walsh MJ, Richardson MM,

Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular

reaction in hepatitis C: roles of impaired replication,

progenitor cells and steatosis. Hepatology. 2005;41(4);809-18.


Sell S. Heterogeneity and plasticity of hepatocyte lineage cells.

Hepatology. 2001;33(3);738-50. https://doi.org/10.1053/


How to Cite
Mendoza, P. G., Tsui, W., Ho, L., Wayne, M., Kagen, A., & Theise, N. (2016). Hepatocellular-Cholangiocarcinomas in Non-Alcoholic Fatty Liver Disease: Evidence for Stem Cell Origin. Philippine Journal of Pathology, 1(1), 30. Retrieved from https://philippinejournalofpathology.org/index.php/PJP/article/view/33
Case Reports